What Does the Research Say About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Occupational Exposure Concern

If you or a loved one has taken Reglan and developed uncontrollable facial or body movements, you may be experiencing tardive dyskinesia. Medical research has established a clear link between prolonged Reglan use and this often irreversible condition. This page reviews the published evidence on risk factors, symptom patterns, and what patients should know.

Reglan and Tardive Dyskinesia: Medical Evidence and FDA Warnings

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning emphasizes that Reglan should be used for the shortest duration necessary and that patients should be periodically reassessed for continued need. In patients with symptomatic gastroesophageal reflux, the maximum duration of treatment is 12 weeks, and in those with diabetic gastroparesis, treatment should not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may not resolve even after discontinuation of the causative medication. The clinical presentation often includes grimacing, lip smacking, tongue protrusion, and rapid eye blinking. Diagnosis is based on clinical evaluation, including a history of exposure to a dopamine-blocking agent like metoclopramide, and ruling out other causes of movement disorders. The mechanistic pathway linking Reglan to TD involves chronic blockade of dopamine D2 receptors in the striatum, leading to upregulation of these receptors and subsequent hypersensitivity to dopamine, which manifests as involuntary movements. This process is dose- and duration-dependent, with longer exposure increasing the likelihood of developing TD.

Legal Considerations and Statute of Limitations in Massachusetts

The adequacy of warnings regarding Reglan and TD is a critical risk anchor. The FDA boxed warning clearly states that Reglan can cause TD and that the risk increases with treatment duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also notes that Reglan is contraindicated in patients with a history of TD and that the drug should be immediately discontinued if signs or symptoms of TD appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may have been prescribed Reglan for longer than recommended durations, or without adequate monitoring, potentially leading to harm. For affected patients, attorney-related considerations include evaluating whether the prescribing physician adhered to the recommended treatment duration and monitoring guidelines, and whether the patient was adequately informed of the risk of TD. The statute of limitations for filing a lawsuit in Massachusetts is a key factor, as it sets a time limit on when legal action can be taken. In Massachusetts, the statute of limitations for personal injury claims, including those related to medication-induced harm, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For TD, this timeline may be complicated by the fact that symptoms can develop gradually and may not be immediately recognized as related to Reglan use. The timeline between exposure to Reglan and documented harm is variable. TD can develop after months or years of continuous use, but it can also occur after shorter periods, especially in patients with risk factors such as older age, female sex, and diabetes. The FDA warning notes that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In some cases, TD may be reversible if detected early and the medication is discontinued promptly, but it can become permanent. The latency period between initial exposure and symptom onset can range from weeks to years, making it challenging to establish a clear causal link in some cases. For legal purposes, documenting the duration of Reglan use, the dosage, and the timing of symptom onset is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims, including those related to medication-induced harm such as tardive dyskinesia from Reglan, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Because TD symptoms can develop gradually, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that their condition was linked to Reglan use. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable time frame.

What are the FDA warnings about Reglan and tardive dyskinesia?

The FDA has issued a boxed warning for Reglan (metoclopramide) stating that it can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk increases with duration of treatment and total cumulative dosage. The warning emphasizes that Reglan should be used for the shortest duration necessary (typically no more than 12 weeks) and that patients should be periodically reassessed. If signs or symptoms of TD appear, the drug should be immediately discontinued. For more details, see the FDA label at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed: Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.